Tozorakimab: a dual-pharmacology anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction
Autor: | I C Scott, E England, D G Rees, T Erngren, C Chaillan Huntington, K F Houslay, D A Sims, C Hollins, E C Hinchy, C Colley, D J Corkill, E S Cohen |
---|---|
Rok vydání: | 2022 |
Zdroj: | 05.01 - Airway pharmacology and treatment. |
Databáze: | OpenAIRE |
Externí odkaz: |